Research programme: cell therapies - Stem Cell Medicine
Alternative Names: MPC-NTFsLatest Information Update: 28 Dec 2022
At a glance
- Originator Tel Aviv University; Weizmann Institute of Science
- Developer Stem Cell Medicine
- Class Gene therapies; Immunotherapies; Stem cell therapies
- Mechanism of Action Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Neuropathic pain; Peripheral nerve injuries
Most Recent Events
- 28 Dec 2022 No recent reports of development identified for preclinical development in Neuropathic-pain in Israel (Parenteral)
- 28 Dec 2022 No recent reports of development identified for preclinical development in Peripheral-nerve-injuries in Israel (Parenteral)
- 01 Nov 2018 Stem Cell Medicine plans to initiate phase II trial for Pain and Neurological diseases